Zometa, Novartis AG's bone-building drug, lowered the chances of breast cancer recurrence by 35% in premenopausal women with early-stage, hormone-sensitive breast cancer when combined with hormone therapy, a study of more than 1,800 patients found. The findings also showed that 9% of those who did not take Zometa in addition to hormone treatments either died or experienced a recurrence, compared with 6% of those who received the drug.

Related Summaries